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Canine acute diarrhoea is frequently observed in first opinion practice, though little is
known about commonly used diagnostic or therapeutic management plans, including
use of antimicrobials. This retrospective observational study utilised electronic health
records augmented with practitioner-completed questionnaires from 3,189 cases (3,159
dogs) collected from 179 volunteer veterinary practices between April 2014 and
January 2017. We used multivariable analysis to explore factors potentially associated
with pharmaceutical agent prescription, and resolution of clinical signs by 10 days
post-initial presentation. Use of bacteriological and/or parasitological diagnostic tests
were uncommon (3.2% of cases, 95% confidence interval, CI, 2.4–4.0), though systemic
antimicrobials were the most commonly prescribed pharmaceutical agents (49.7%
of cases, 95% CI 46.1–53.2). Such prescription was associated with haemorrhagic
diarrhoea (odds ratio, OR, 4.1; 95% CI 3.4–5.0), body temperature in excess
of 39.0◦C, or moderate/severe cases (OR 1.3, 95% CI 1.1–1.7). Gastrointestinal
agents (e.g., antacids) were prescribed to 37.7% of cases (95% CI 35.4–39.9),
and were most frequently prescribed to vomiting dogs regardless of presence (OR
46.4, 95% CI 19.4–110.8) or absence of blood (OR 17.1, 95% CI 13.4–21.9).
Endoparasiticides/endectocides were prescribed to 7.8% of cases (95% CI 6.8–9.0),
such prescription being less frequent for moderate/severe cases (OR 0.5, 95% CI
0.4–0.7), though more frequent when weight loss was recorded (OR 3.4, 95% CI
1.3–9.0). Gastrointestinal nutraceuticals (e.g., probiotics) were dispensed to 60.8% of
cases (95% CI 57.1–64.6), these cases less frequently presenting with moderate/severe
clinical signs (OR 0.6, 95% CI 0.5–0.8). Nearly a quarter of cases were judged lost to
follow-up (n=754). Insured (OR 0.7, 95%CI 0.5–0.9); neutered (OR 0.4, 95%CI 0.3–0.5),
or vaccinated dogs (OR 0.3, 95% CI 0.3–0.4) were less commonly lost to follow-up.
Of remaining dogs, clinical signs were deemed resolved in 95.4% of cases (95% CI
94.6–96.2). Provision of dietary modification advice and gastrointestinal nutraceuticals
alone were positively associated with resolution (OR 2.8, 95% CI 1.3–6.1); no such
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associations were found for pharmaceutical agents, including antimicrobials. Hence, this
study supports the view that antimicrobials are largely unnecessary for acute diarrhoea
cases; this being of particular importance when considering the global threat posed by
antimicrobial resistance.
Keywords: health informatics, antimicrobial resistance, companion animal, electronic health record,
pharmacosurveillance, acute canine diarrhoea, haemorrhagic diarrhoea
INTRODUCTION
Acute diarrhoea commonly affects dogs (1). Whilst the majority
of cases are generally mild and self-limiting, some can be life
threatening (2–7). Aetiology is complex, including a range of
non-infectious lifestyle factors, such as a history of scavenging
or being fed home-cooked diets (1, 5, 6). Zoonotic (e.g.,
Campylobacter, Salmonella, Giardia spp.) and non-zoonotic (e.g.,
canine parvovirus, canine enteric coronavirus) pathogens have
also been implicated (6, 8–14), though the precise role some of
these play remains of debate (8, 15–18). A range of therapeutic
options are available, either targeting potential infectious agents
and/or clinical signs (2, 5). Together this creates a complex
clinical decision-making environment for practitioners when
first presented with such cases, further compounded by relatively
infrequent use of diagnostic testing (5).
Antimicrobial prescription, as a management strategy, is a
particular focus for research due to the increasing threat posed
by antimicrobial resistance (19). Antimicrobial prescription has
been recorded in between 45 and 70% of canine diarrhoea
cases (2, 5, 7, 20, 21), with prescription being most frequent
in cases presenting with pyrexia or haemorrhagic diarrhoea
(2, 5). These findings most likely reflect a perception that
such clinical signs increase likelihood of infectious process
involvement and/or intestinal mucosal compromise, increasing
risk of bacteraemia (15). However, recent case-control studies
of canine acute haemorrhagic diarrhoea syndrome (AHDS) have
questioned whether antimicrobial therapy has an impact on odds
of recovery in non-septic patients (10, 22), and indeed whether
antimicrobials should be prescribed at all (10, 16, 23).
In addition to antimicrobial prescription, management
strategies frequently encompass other pharmaceutical agents
both as primary diarrhoea therapies (24), or tomanage associated
clinical signs (2). The potential utility of gastrointestinal
nutraceuticals (including prebiotics, probiotics, adsorbents, and
motility modifiers) has also attracted recent attention (25, 26),
though evidence of in vivo efficacy remains limited (25).
The complex and often undetermined aetiology of acute
canine diarrhoea, as well as the range of therapeutic or
management interventions available, provides a natural
opportunity to more fully understand factors that might drive
complex clinical decision-making in practice, as well as which
of these decisions might impact outcome. This study aimed
to combine electronic health record (EHR) and questionnaire
data collected from a large network of UK veterinary practices
to explore factors associated with the decision to prescribe
pharmaceutical agents or dispense nutraceuticals to dogs
presenting with acute diarrhoea.
MATERIALS AND METHODS
Data Collection
This longitudinal retrospective study analysed electronic health
records (EHRs) collected from 179 volunteer veterinary practices
(347 sites) situated in the United Kingdom (UK) that
participate in the Small Animal Veterinary Surveillance Network
(SAVSNET) and utilise Robovet practice management software
(Vet Solutions Ltd.). A veterinary practice was defined as a single
business, whereas “sites” included all branches that comprised an
individual veterinary practice. SAVSNET hold ethical approval
from the University of Liverpool (RETH000964); data collection
protocols are more fully described elsewhere (4). Briefly, EHRs
were collected from consultations where a booked appointment
was made to see a veterinary professional (veterinary surgeon
or veterinary nurse) between 1 April 2014 and 31 January 2017.
Every consultation was classified by the consulting veterinary
professional into one of ten categories indicating the main reason
that the animal presented and the main presenting complaint
(MPC) (21). In addition to the MPC, a further questionnaire
was completed in a random selection of consultations by the
attending veterinary professional (Table 1). Consultations which
had been classified into the “gastroenteric” MPC, which also had
an associated completed questionnaire attached were selected for
inclusion in this study.
A case was defined as a dog presenting for investigation of
acute diarrhoea (Table 1, question 1) of 2 days or less duration
(Table 1, question 5), where the relevant consultation was the first
time the animal had presented for investigation of that diarrhoeic
episode (Table 1, question 4). Consultations were selected for
presence of diarrhoea but not at the exclusion of other clinical
signs. In addition to a range of signalment data (e.g., age, sex,
breed etc.), the MPC, and the associated questionnaire responses,
each EHR also included a text-based product description and free
text clinical narrative. The latter was manually interrogated to
summarise animal body temperature (if recorded). Each EHR
also contained a vaccination history; animals were defined as
currently vaccinated if they had received a vaccination of any
composition within 3.5 years preceding the relevant consultation
date (27).
Pharmaceutical, Nutraceutical, or
Veterinary Professional Advice
Identification
Pharmaceutical agent prescriptions were identified and classified
via the semi-structured text-based product description field
of the EHR (28). Antimicrobials and anti-inflammatories
were further classified by authorised administration route as
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TABLE 1 | Questions provided to consulting veterinary professionals in ∼10% of
consultations (selected at random) where they had selected “gastrointestinal” as
the main reason the owner presented the animal to the practice.
Question Answer options
1. Please indicate the clinical
signs present
Diarrhoea without blood
Diarrhoea with blood
Vomiting without blood
Vomiting with blood
Melaena
Weight loss/failure to gain weight
Poor appetite
Other
2. If diarrhoea was present how
would you describe it?
Small intestinal diarrhoea
Large intestinal diarrhoea/colitis
Mixed pattern
No diarrhoea
Don’t know
3. Please indicate disease severity Mild illness i.e., normal apart from GI disease
Moderately ill
Severely ill/debilitated
4. How does this consultation relate
to this episode of illness?
First presentation
Revisit/check-up
Don’t know
5. How long approximately has the
pet had this episode of illness?
Up to 2 days
Between 3 days and 2 weeks
More than 2 weeks—less than 1 month
1 month and over
Don’t know
6. What diagnostic options will be
used today for this episode
of illness?
None
Faecal parasitology/bacteriology
Faecal virology
Virus serology
Diagnostic imaging
Haematology/biochemistry
Serum B12/Folate and/or serum TLI
Canine/feline specific pancreatic lipase
Urinalysis
Other
7. What advice did you give today? Change of diet
Fasting
Admit patient for treatment
Refer patient
Check-up in near future
Other
systemic (oral or injectable forms, hence “systemic”) or topical
administration (aural, ocular, skin). Five pharmaceutical families
commonly prescribed for management of canine gastroenteric
disease (5) were selected for further analyses: systemic
antimicrobials (excluding topical antimicrobials), systemic
anti-inflammatories (excluding topical anti-inflammatories),
gastrointestinal agents e.g., antacids, gastro-protectants, anti-
emetics etc., endoparasiticides and endectocides, and products
used for euthanasia (henceforth, “euthanasia”). Additionally, the
product description field was interrogated to identify dispensed
gastrointestinal nutraceutical products. These were defined as
products not listed as either authorised veterinary or human
medicinal products which contained a range of probiotics,
prebiotics, kaolin etc., and were marketed for the purpose of
aiding diarrhoea resolution.
Case Follow-Up
As the majority of canine self-limiting diarrhoea cases resolve
within a week (29), cases were considered as resolved if they did
not return to the veterinary practice for a mainly gastroenteric
reason (as judged by MPC) between 11 and 30 days post-initial
presentation. The clinical narratives for all cases re-presenting for
examination between 1 and 10 days post-initial presentation were
additionally read to record explicit mention of diarrhoeic clinical
sign resolution, and any further pharmaceutical prescriptions
provided in this time period. Cases were defined as lost to follow-
up if they did not re-present to the veterinary practice at all by
31 January 2018, or were seen again within 10 days post-initial
presentation but did not re-present by 31 January 2018.
Statistical Analyses
All analyses were carried out using R language (version 3.4.4).
Descriptive proportions and associated 95% confidence intervals
(95% CI) were calculated to adjust for clustering (bootstrap
method, n= 5,000 samples) within site,1 encompassing a range of
binary or categorical demographic, clinical sign, pharmaceutical
agent prescription, and clinical outcome variables. Median
and range were calculated for continuous variables. Following
descriptive analyses, univariable and multivariable mixed effects
logistic regression were used to model a range of outcomes,
using the R package “lme4”2 Primary outcomes, modelled as
binary variables, included resolution of diarrhoea clinical signs
(as defined above), and loss to follow-up. The decision to
prescribe systemic antimicrobials, systemic anti-inflammatories,
gastrointestinal agents, endoparasiticides and endectocides, and
to euthanise the dog at initial presentation were also explored,
using prescription of such agents as binary independent variables
in separate models. A likelihood ratio test (LRT) of a null model
indicated that observations were clustered within practice and
site; hence both were included as random effects in all models.
Univariable regression was first performed, with explanatory
variables being retained if a LRT indicated P ≤ 0.20 against a
null model.
In total, 21 binary or categorical explanatory variables were
considered. For all models, these included factors related to
animal signalment (insurance status, vaccination status, sex,
neutered status, microchip status); questionnaire responses
(presence of haemorrhagic diarrhoea, melaena, vomiting,
decreased appetite, weight loss, diarrhoeic pattern, clinical
severity) and categorised body temperature as recorded within
the clinical narrative attached to each consultation (interpreted
normal or below 39.0◦C, 39.0–39.4◦C, 39.5–39.9◦C, in excess
1AOD Package. Available from: https://cran.r-project.org/package=aod
2LME4 Package. Available from: https://cran.r-project.org/package=lme4
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of 40.0◦C, and temperature not recorded), as recorded within
the clinical narrative attached to each consultation. Considering
clinical severity, due to a low number of severe cases such cases
were combined into a single category with moderate cases for all
models. Animal’s age at consultation was fitted as a continuous
explanatory variable; where relevant, polynomial terms were
fitted if an LRT indicated significantly improved fit.
For models considering resolution or loss to follow-up only,
questionnaire responses indicating that the consulting veterinary
professional had provided advice to either modify the animal’s
diet or fast the animal were also considered. Prescription
of pharmaceutical agents or dispensed gastrointestinal
nutraceuticals were also included in resolution and loss to
follow-up models as binary dependent variables.
In order to take into account the therapeutic complexities
surrounding case management, we took three separate
approaches to modelling the association of each of the five
therapeutic options (e.g., the four investigated pharmaceutical
families and gastrointestinal nutraceuticals) and dietary
modification advice against case resolution. Firstly, we
considered each option/advice regardless of presence of
other options e.g., a single case must be prescribed a systemic
antimicrobial, but could also be prescribed/dispensed/advised
any other option. Secondly, we considered each option/advice in
isolation e.g., a single case could only be prescribed a systemic
antimicrobial, with no further prescription/dispensing/advice
provided. Finally, we also considered dietary advice in
combination with each option in isolation e.g., a single case must
be provided with dietary modification advice and prescribed a
systemic antimicrobial, with no further options provided.
Multivariable analyses underwent step-wise backward
elimination to reduce Akaike Information Criterion (AIC) and
Bayesian Information Criterion (BIC). Two-way interaction
terms were assessed for improved multivariable model fit via a
combination of AIC and BIC. Multicollinearity was assessed in
the final model via use of the Variance Inflation Factor (VIF),
available through the R package “car”3 Odds ratios, confidence
intervals, correlation of fixed effects and projected probabilities
were calculated utilising the R package “sjPlot”4 Statistical
significance was defined throughout as P < 0.05.
RESULTS
Study Population
In total, 12,455 questionnaires were completed for canine
patients (11,589 unique dogs) with a gastroenteric MPC, of
which 3,192 questionnaires (3,162 unique dogs) fitted the acute
diarrhoea case definition (two days or less duration and first
presentation for examination). Three dogs were removed where
a spurious date of birth was recorded (e.g., 1st January 1900).
Hence, 3,189 diarrhoea cases (involving 3,159 unique dogs)
collected from 179 veterinary practices (347 sites) were included
in analyses (Figure 1). Of these retained cases, 50.2% (95%
CI, 48.3–52.1) were recorded as male; 62.2% of male cases
3CAR Package. Available from: https://cran.r-project.org/package=car.
4sjPlot Package. Available from: https://cran.r-project.org/package=sjPlot
FIGURE 1 | Flow diagram showing case selection procedure for prescription
modelling, loss to follow-up, and outcome modelling.
were neutered (95% CI 59.6–64.9), 72.4% of female cases were
neutered (95% CI 69.7–75.1), 54.6% of total retained cases
were microchipped (95% CI 52.1–57.2), 24.4% of total retained
cases were insured (95% CI 22.1–26.7), and 73.6% of total
retained cases has been vaccinated within the preceding 3.5
years (95% CI 71.5–75.8). Median age at initial presentation was
4.2 years (range 0.0–18.5).
Descriptive Analyses
Cases were considered by clinical severity (Table 1, question
3), clinical sign combinations (Table 1, question 1), and body
temperature as recorded in the clinical narrative. The majority
of dogs [n = 1,893; 59.4% of cases (95% CI 57.8–61.0)]
initially presented with non-haemorrhagic diarrhoea (Table 2).
Most cases were recorded as mild (n = 2,665; 83.6% of
cases, 95% CI 82.2–85.0), with moderate cases more commonly
reporting diarrhoea with blood, vomiting, weight loss, poor
appetite, and a mixed diarrhoeic pattern compared to mild
cases. Utilisation of diagnostic tests was uncommon (<10% of
all cases), with bacteriology and parasitology being the most
commonly performed test (3.2% of cases, 95% CI 2.4–4.0).
Dietary modification was the most commonly provided advice
to dog owners. In total, 1,812 cases explicitly recorded body
temperature within the clinical narrative, reporting a median
body temperature of 38.6◦C (range 36.2–41.3); a further 53
and 3 cases recorded a “normal” or “increased” temperature,
respectively without stating a value. Considered together, an
interpreted normal or below 39.0◦C body temperature was
recorded in 58.4% of cases (n = 1,865, 95% CI 56.5–60.4);
39.0◦C−39.4◦C in 13.1% (n = 418, 95% CI 11.8–14.4), 39.5–
39.9◦C in 3.5% (n = 110, 95% CI 2.8–4.1), and >40.0◦C in 0.9%
of cases (n= 30, 95% CI 0.6–1.3). Temperature was not recorded
or interpreted in 23.9% of cases (n = 763, 95% CI 21.9–25.9). A
greater proportion of cases were classified as moderate or severe
as reported temperature increased (data not presented).
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TABLE 2 | Descriptive summary of questionnaire responses for both the entire study population and when stratified by the consulting veterinary professional’s assessed
case severity, according to questionnaire responses.
Question Response All cases
(n = 3,189 cases)
Mild case
(n = 2,665 cases)
Moderate case
(n = 507 cases)
Severe case
(n = 17 cases)
% (95% CI)a % (95% CI) % (95% CI) % (95% CI)
1. Clinical signs Diarrhoea without blood 59.4 (57.8–61.0) 60.2 (58.4–62.0) 55.9 (52.0–59.7) 41.8 (17.4–66.1)
Diarrhoea with blood 40.6 (39.0–42.3) 39.9 (38.1–41.6) 44.2 (40.4–48.0) 58.5 (34.3–82.7)
Vomit without blood 33.7 (31.8–35.6) 28.9 (27.0–30.8) 58.8 (54.0–63.6) 41.4 (16.7–66.0)
Vomit with blood 2.3 (1.7–2.9) 2.0 (1.4–2.5) 3.8 (2.1–5.4) 11.8 (0.0–27.3)
Melaena 0.4 (0.2–0.6) 0.2 (0.0–0.3) 1.6 (0.5–2.7) 5.9 (0.0–17.0)
Weight lossb 1.2 (0.8–1.6) 0.8 (0.5–1.1) 3.2 (1.4–4.9) 6.0 (0.0–17.2)
Poor appetite 13.8 (12.4–15.2) 10.3 (8.9–11.6) 31.5 (27.3–35.8) 35.4 (11.9–58.8)
Other 1.6 (1.0–2.2) 1.2 (0.7–1.7) 3.4 (1.5–5.2) 17.9 (0.0–36.4)
2. Pattern Small intestinal 32.7 (30.5–34.8) 31.8 (29.5–34.1) 37.5 (32.7–42.4) 29.6 (7.5–51.8)
Large intestinal 39.0 (36.9–41.1) 41.3 (39.2–43.5) 27.0 (22.6–31.4) 35.4 (12.0–58.8)
Mixed pattern 19.7 (18.0–21.4) 18.2 (16.6–19.9) 26.8 (22.3–31.2) 22.8 (0.0–46.1)
Don’t know 8.7 (7.4–9.9) 8.6 (7.3–10.0) 8.7 (6.3–11.1) 11.9 (0.0–27.1)
3. Diagnostic
options
Total 9.0 (7.7–10.3) 7.7 (6.4–9.0) 13.7 (10.2–17.1) 70.3 (47.9–92.6)
Bacteriology/parasitology 3.2 (2.4–4.0) 3.2 (2.4–4.1) 2.8 (1.3–4.3) 6.0 (0.0–17.3)
Faecal virology 0.1 (0.0–0.3) 0.0 (0.0–0.1) 0.4 (0.0–0.9) 5.9 (0.0–17.1)
Virus serology 0.1 (0.0–0.1) 0.0 (0.0–0.1) 0.2 (0.0–0.6) 0.0 (0.0–0.0)
Diagnostic imaging 0.9 (0.5–1.3) 0.6 (0.3–1.0) 2.0 (0.5–3.5) 11.7 (0.0–25.8)
Haematology/biochemistry 2.4 (1.8–3.1) 1.4 (0.9–1.8) 6.1 (3.8–8.4) 52.7 (27.9–77.5)
Serum B12 and/or TLI 0.1 (0.0–0.2) 0.1 (0.0–0.2) 0.2 (0.0–0.6) 0.0 (0.0–0.0)
Specific pancreatic lipase 0.6 (0.3–0.9) 0.4 (0.2–0.6) 1.6 (0.4–2.8) 11.8 (0.0–27.4)
Urinalysis 0.3 (0.1–0.4) 0.3 (0.1–0.5) 0.2 (0.0–0.6) 0.0 (0.0–0.0)
Other 3.1 (2.4–3.9) 2.9 (2.1–3.6) 4.1 (2.3–5.9) 17.6 (0.0–35.8)
4. Advice Change of diet 69.8 (67.3–72.4) 71.1 (68.5–73.8) 65.0 (60.2–69.8) 5.6 (0.0–15.5)
Fasting 19.1 (16.4–21.8) 18.4 (15.5–21.3) 23.0 (18.4–27.5) 5.9 (0.0–17.2)
Admission 2.3 (1.7–3.0) 1.2 (0.7–1.6) 6.5 (4.2–8.8) 58.7 (34.7–82.7)
Refer 0.2 (0.0–0.3) 0.1 (0.0–0.2) 0.2 (0.0–0.6) 5.6 (0.0–15.8)
Check-up 22.9 (20.9–24.9) 20.1 (18.0–22.2) 37.5 (32.9–42.0) 17.0 (0.0–38.8)
Other 49.4 (46.6–52.2) 50.3 (47.2–53.3) 45.3 (40.9–49.8) 35.8 (12.5–59.1)
aPercentage of cases (95% confidence interval).
bWeight loss or failure to gain weight.
Pharmaceutical prescription occurred in 78.4% (95% CI 76.3–
80.5) of initial presentations, rising to 81.3% of cases (95% CI
79.5–83.2) within 10 days post-initial presentation (Table 3).
Systemic antimicrobials were the most commonly prescribed
pharmaceutical agent (49.7% of cases at initial presentation,
rising to 52.5% within 10 days of initial presentation).
Gastrointestinal nutraceuticals were also frequently dispensed
(60.8% of cases at initial presentation, rising to 61.7%
within 10 days of initial presentation). In total, 4.3% of
cases (95% CI 3.4–5.2) had no record of a pharmaceutical
agent being prescribed or a gastrointestinal nutraceutical
dispensed. Metronidazole represented the most commonly
prescribed systemic antimicrobial (47.0% of antimicrobial
prescribing cases, 95% CI 41.0–53.1); glucocorticoids the
most commonly prescribed systemic anti-inflammatory (81.3%
of anti-inflammatory prescribing cases, 95% CI 73.6–89.1);
maropitant the most commonly prescribed gastrointestinal agent
(44.6% of gastrointestinal prescribing cases, 95% CI 39.9–49.3),
and a combination of milbemycins and quinolines were the most
commonly prescribed endoparasiticides/endectocides (48.0% of
endoparasiticide/ endectocide prescribing cases, 95% CI 41.5–
54.5) (see Supplementary Table 1).
Pharmaceutical prescription frequency varied by
case severity, with systemic antimicrobials largely being
prescribed to mild and moderate cases (Table 3), and
showed considerable variation between cases, particularly
in relation to co-prescription (Table 4). Systemic antimicrobial
prescription was more frequent in cases reporting
diarrhoea with blood compared to diarrhoea without
blood, regardless of presence or absence of vomiting
(see Supplementary Table 2).
Factors Associated With Pharmaceutical
or Nutraceutical Intervention
No variables were significant on univariable analyses for systemic
anti-inflammatory prescription (see Supplementary Table 3);
hence no further statistical analysis was performed for this
prescription category.
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TABLE 3 | Descriptive summary of pharmaceutical prescriptions and dispensing of nutraceutical products both at initial presentation and when the subsequent 9 days
(inclusive) post-presentation were considered.
Category All cases Mild case Moderate case Severe case
% (95% CI)a % (95% CI) % (95% CI) % (95% CI)
THERAPY—INITIAL PRESENTATION
Pharmaceutical agent 78.4 (76.3–80.5) 76.4 (74.0–78.9) 89.4 (86.8–92.0) 58.9 (36.7–81.1)
Systemic antimicrobial 49.7 (46.1–53.2) 48.2 (44.5–51.9) 58.5 (53.4–63.7) 5.9 (0.0–17.2)
Systemic anti-inflammatory 14.2 (10.6–17.8) 14.2 (10.5–17.9) 15.0 (10.1–19.9) 0.0 (0.0–0.0)
Gastrointestinal agent 37.7 (35.4–39.9) 33.3 (31.0–35.6) 60.9 (56.5–65.4) 17.5 (0.3–34.6)
Endoparasiticide and/or endectocide 7.8 (6.8–9.0) 8.7 (7.5–10.0) 3.6 (2.0–5.2) 0.0 (0.0–0.0)
Gastrointestinal nutraceutical 60.8 (57.1–64.6) 63.0 (59.1–66.9) 51.1 (46.0–56.3) 11.9 (0.0–27.5)
Euthanasia/death 0.2 (0.0–0.3) 0.0 (0.0–0.0) 0.0 (0.0–0.0) 35.3 (11.9–58.8)
THERAPY—INITIAL PRESENTATION AND/OR WITHIN 10 DAYS OF INITIAL PRESENTATION
Pharmaceutical agent 81.3 (79.5–83.2) 79.6 (77.4–81.8) 91.1 (88.7–93.6) 59.0 (37.0–81.1)
Systemic antimicrobial 52.5 (49.1–55.8) 51.2 (47.7–54.6) 61.1 (56.2–66.1) 5.9 (0.0–17.3)
Systemic anti-inflammatory 15.3 (11.6–19.0) 15.4 (11.8–19.1) 15.3 (10.5–20.2) 0.0 (0.0–0.0)
Gastrointestinal agent 39.0 (36.7–41.2) 34.7 (32.3–37.2) 62.0 (57.6–66.4) 17.6 (0.4–34.8)
Endoparasiticide and/or endectocide 9.5 (8.3–10.7) 10.6 (9.2–11.9) 4.3 (2.4–6.1) 0.0 (0.0–0.0)
Gastrointestinal nutraceutical 61.7 (58.1–65.4) 63.7 (59.8–67.5) 53.4 (47.9–58.9) 12.0 (0.0–27.5)
Euthanasia/death 0.4 (0.2–0.6) 0.2 (0.0–0.3) 0.2 (0.0–0.6) 35.4 (12.1–58.8)
OUTCOME
Resolution (10 day) 72.6 (70.3–75.0) 73.9 (71.4–76.3) 67.7 (63.2–72.0) 29.5 (9.1–49.9)
Lost to follow-up 23.7 (21.4–26.0) 22.5 (20.2–24.9) 29.0 (24.7–33.2) 35.3 (13.8–56.8)
Longitudinal outcome is also displayed, with all comparisons shown when considered by consulting veterinary professional assessment of case severity at initial presentation.
aPercentage of cases (95% confidence interval).
TABLE 4 | Descriptive summary of cases where multiple sets of advice, nutraceutical dispensing, or pharmaceutical prescriptions were provided, expressed as a
percentage of total cases where each “event type” was provided.
Event type Percentage (%) of total advice/dispensing/prescription events, by event type
Total
events
Diet
change
Fast Gastrointestinal
nutraceutical
Systemic
antimicrobial
Systemic
anti-inflammatory
Gastrointestinal
agent
Endoparasiticide/
endectocide
Diet change 2,227 14.0 64.3 49.0 13.4 37.0 7.7
Fast 608 52.0 54.1 50.0 22.2 43.8 5.1
Gastrointestinal
nutraceutical
1,939 73.9 17.0 40.7 8.9 33.5 9.0
Systemic antimicrobial 1,585 68.9 19.0 49.8 18.2 37.2 6.0
Systemic
anti-inflammatory
454 65.6 30.0 38.1 63.7 26.7 4.0
Gastrointestinal agent 1,200 68.6 22.0 54.2 49.2 10.1 4.2
Endoparasiticide/
endectocide
250 68.4 12.0 70.0 38.0 7.2 20.0
For example, a gastrointestinal nutraceutical was also dispensed to 64.3% of cases where “diet change” advice was provided (n = 2,227).
Systemic Antimicrobial Prescription
Dogs presenting with diarrhoea with blood were more frequently
prescribed a systemic antimicrobial (Odds ratio, OR, 4.1, 95%
CI, 3.4–5.0), compared to diarrhoea without blood; moderate
or severe cases were also more frequently prescribed a systemic
antimicrobial compared to mild cases (OR 1.3, 95% CI 1.1–1.7)
(Table 5). Compared to an interpreted normal or below 39◦C
body temperature at initial presentation, all other temperature
categories were more frequently associated with prescription,
peaking at between 39.5 and 39.9◦C (OR 5.9, 95% CI 3.6–9.9).
Prescription probability increased with age up to∼7 years of age,
but remained static between seven and thirteen, and increased
from thirteen years of age upwards (Figure 2A). Results from
univariable analyses are available in Supplementary Table 4. A
cubic polynomial termwas included tomodel age at consultation;
no interaction terms significantly improved the fit of the model.
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TABLE 5 | Parameter estimates from a finalised mixed effects logistic regression model, modelling on a case-level the presence of systemic antimicrobial and
gastrointestinal agent prescription against a range of risk factors.
Random effect Variance SDa Variable Category β SEb ORc (95% CI)d P
SYSTEMIC ANTIMICROBIAL PRESCRIPTION
Practice 0.75 0.87 Intercept −0.72 0.14 0.49 (0.37–0.64)
Site 0.27 0.52 Diarrhoea Without blood - - 1.00 -
With blood 1.42 0.10 4.13 (3.42–4.98) <0.01
Weight loss Absent - - 1.00 -
Present 0.71 0.40 2.03 (0.93–4.45) 0.08
Severity Mild - - 1.00 -
Moderate/severe 0.29 0.12 1.34 (1.06–1.69) 0.01
Diarrhoeic pattern Large intestinal - - 1.00 -
Mixed 0.01 0.13 1.01 (0.78–1.30) 0.95
Small intestinal 0.07 0.11 1.07 (0.87–1.31) 0.54
Unknown −0.53 0.17 0.59 (0.42–0.82) <0.01
Body temperature Normal/<39◦C - - 1.00 -
Not recorded 0.18 0.11 1.19 (0.97–1.46) 0.09
39.0◦C ≤ 39.4◦C 0.72 0.13 2.05 (1.58–2.65) <0.01
39.5◦C ≤ 39.9◦C 1.78 0.26 5.93 (3.56–9.88) <0.01
40.0◦C ≤ 1.50 0.48 4.47 (1.76–11.36) <0.01
Age (years) Age—linear 0.22 0.08 1.25 (1.07–1.46) 0.01
Age—quadratic −0.25 0.08 0.78 (0.67–0.91) <0.01
Age—cubic 0.10 0.05 1.10 (1.01–1.20) 0.04
GASTROINTESTINAL AGENT PRESCRIPTION
Practice 0.32 0.56 Intercept −1.65 0.13 0.19 (0.15–0.25)
Site 0.28 0.53 Vomit No vomit - - 1.00 -
Without blood 2.84 0.13 17.13 (13.41–21.89) <0.01
With blood 3.84 0.45 46.35 (19.39–110.81) <0.01
Poor appetite Absent - - 1.00 -
Present 0.65 0.15 1.92 (1.45–2.55) <0.01
Severity Mild - - 1.00 -
Moderate & severe 0.93 0.19 2.52 (1.76–3.62) <0.01
Diarrhoeic pattern Large intestinal - - 1.00 -
Mixed 0.28 0.14 1.33 (1.00–1.76) 0.05
Small intestinal 0.20 0.11 1.22 (0.97–1.53) 0.08
Unknown 0.01 0.18 1.01 (0.70–1.44) 0.98
Body temperature Normal/<39◦C - - 1.00 -
Not recorded −0.38 0.12 0.68 (0.54–0.87) <0.01
39.0◦C ≤ 39.4◦C −0.04 0.15 0.96 (0.72–1.28) 0.78
39.5◦C ≤ 39.9◦C −0.17 0.25 0.84 (0.51–1.39) 0.50
40.0◦C ≤ −1.05 0.50 0.35 (0.13–0.93) 0.04
Vomit & Severity No blood:
moderate/severe
−0.71 0.25 0.49 (0.30–0.80) 0.01
With blood:
moderate/severe
-2.07 0.73 0.13 (0.03–0.53) 0.01
Age (years) Age—linear 0.13 0.09 1.13 (0.95–1.35) 0.17
Age—quadratic −0.33 0.09 0.72 (0.60–0.87) <0.01
Age—cubic 0.09 0.05 1.10 (0.99–1.21) 0.08
Bold values are indicate significant findings.
aStandard Deviation.
bStandard Error.
cOdds Ratio.
d95% Confidence Interval.
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FIGURE 2 | (A) Projections from a series of multivariable logistic regression models, estimating the probability of a range of pharmaceutical agents being prescribed at
initial presentation for diarrhoea, when considered against age at presentation (in years). (B) Estimates of longitudinal outcome, including probability of a case being
lost to follow-up or being considered resolved of diarrhoeic clinical signs 10 days post-initial presentation. Lines refer to predicted probability, with shading relating to
95% confidence intervals to such predictions. Points are plotted to show original data points expressing the percentage of animals of each relevant age group
(rounded to 2 year groups) that were prescribed a pharmaceutical agent, or were classified into the resolved or lost to follow-up categories.
Gastrointestinal Agent Prescription
Compared to non-vomiting dogs, dogs vomiting with or without
blood were much more frequently prescribed a gastrointestinal
agent (Table 5). Non-vomiting moderate and severe cases were
also more frequently prescribed compared to non-vomiting mild
cases (OR 2.5, 95%CI 1.8–3.6). Prescription probability increased
up to approximately 6 years of age, before decreasing until 15
years of age (Figure 2A). Univariable results are available in
Supplementary Table 5. A cubic polynomial term was included
to model age at consultation; an interaction term between case
severity and vomiting significantly improved the fit of the model.
Endoparasiticide/Endectocide Prescription
Animals reported to have lost weight were associated with
increased odds (OR 3.4, 95% CI 1.3–9.0) of endoparasiticide
and/or endectocide prescription, though moderate and severe
cases (OR 0.4, 95% CI 0.3–0.7) or vomiting cases without
blood (OR 0.5, 95% CI 0.4–0.7) were less frequently prescribed
(Table 6). Vaccinated animals were also less frequently (OR 0.6,
95% CI 0.4–0.7) prescribed at initial presentation. Prescription
probability decreased sharply up to 3 years of age, remained
broadly stable until 12 years of age, and then decreased
further (Figure 2A). Univariable results are available in
Supplementary Table 6. A cubic polynomial term was included
to model age at consultation; no interaction terms significantly
improved the fit of the model.
Dispensing of Gastrointestinal Nutraceuticals
A number of clinical signs including diarrhoea with blood (OR
0.7, 95% CI 0.6–0.9), vomiting with (OR 0.3, 95% CI 0.2–0.5)
or without blood (OR 0.6, 95% CI 0.5–0.7), body temperature
between 39.5 and 39.9◦C (OR 0.5, 95% CI 0.3–0.8), other clinical
signs (OR 0.4, 95% CI 0.2–0.7), and moderate and severe cases
(OR 0.6, 95% CI 0.5–0.8) were all less frequently associated
with a gastrointestinal nutraceutical being dispensed (Table 6).
However, a mixed diarrhoeic pattern was associated with
increased odds (OR 1.33, 95% CI 1.04–1.71). Odds decreased
with age to approximately 4 years of age and remained broadly
static until 10 years of age, before decreasing further (Figure 2A).
Univariable results are available in Supplementary Table 7. A
cubic polynomial termwas included tomodel age at consultation;
no interaction terms significantly improved the fit of the model.
Analysis of Longitudinal Outcomes
Cases Lost to Follow-Up
In total, 754 cases (23.6% of total cases) were lost to follow-up.
Currently insured (OR 0.7, 95% CI 0.5–0.9), recently vaccinated
(OR 0.3. 95% CI 0.3–0.4) or neutered (OR 0.4, 95% CI 0.3–
0.5) dogs had lower odds of being lost to follow-up (Table 7).
Increasing age was associated with increased probability of a
case being lost to follow-up until approximately 4 years of age,
decreasing slightly between four and twelve, before increasing
once more (Figure 2B). Univariable results are available in
Supplementary Table 8. A cubic polynomial term was included
to model age at consultation; no interaction terms significantly
improved the fit of the model.
Diarrhoea Resolution
Cases euthanised on initial presentation (n = 6) and lost
to follow-up (n = 754) were excluded, leaving 2,429 cases
available for resolution analyses. By the 10th day following
initial presentation, 95.4% (95% CI 94.5–96.3) of cases were
considered resolved; 7.6% of resolved cases were recorded as
such in the clinical narrative, the remaining cases were assumed
to be resolved by the absence of any further gastrointestinal-
related consultations between 11 and 30 days following
initial presentation.
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TABLE 6 | Parameter estimates from a finalised mixed effects logistic regression model, modelling on a case-level the presence of endoparasiticide/endectocide
prescription and dispensing of gastrointestinal nutraceuticals against a range of risk factors.
Random effect Variance SDa Variable Category β SEb ORc (95% CI)d P
ENDOPARASITICIDE/ENDECTOCIDE PRESCRIPTION
Practice 0.28 0.53 Intercept −2.38 0.19 0.09 (0.06–0.14)
Site 0.21 0.46 Vomit No vomit - - 1.0 -
Without blood −0.69 0.18 0.50 (0.36–0.71) <0.01
With blood −1.04 0.74 0.35 (0.08–1.50) 0.16
Weight loss Absent - - 1.0 -
Present 1.22 0.50 3.37 (1.27–9.00) 0.02
Severity Mild - - 1.0 -
Moderate & severe −0.83 0.27 0.44 (0.26–0.74) <0.01
Vaccination status Unvaccinated - - 1.0 -
Vaccinated −0.59 0.15 0.55 (0.42–0.74) <0.01
Age (years) Age—linear 0.07 0.18 1.07 (0.76–1.51) 0.70
Age—quadratic 0.57 0.14 1.77 (1.35–2.32) <0.01
Age—cubic −0.36 0.11 0.70 (0.57–0.87) <0.01
GASTROINTESTINAL NUTRACEUTICAL DISPENSING
Practice 0.64 0.80 Intercept 0.93 0.16 2.52 (1.85–3.43)
Site 0.21 0.45 Diarrhoea Without blood - - 1.0 -
With blood −0.31 0.09 0.74 (0.62–0.88) <0.01
Vomit No vomit - - 1.0 -
Without blood −0.57 0.09 0.57 (0.47–0.68) <0.01
With blood −1.34 0.29 0.26 (0.15–0.46) <0.01
Other signs Absent - - 1.0 -
Present −0.99 0.33 0.37 (0.19–0.71) <0.01
Severity Mild - - 1.0 -
Moderate & severe −0.48 0.12 0.62 (0.49–0.78) <0.01
Diarrhoeic pattern Large intestinal - - 1.0 -
Mixed 0.29 0.13 1.33 (1.04–1.71) 0.02
Small intestinal 0.21 0.11 1.23 (1.00–1.51) 0.05
Unknown −0.20 0.16 0.82 (0.60–1.12) 0.22
Body temperature Normal/<39◦C - - 1.0 -
Not recorded −0.50 0.10 0.61 (0.50–0.74) <0.01
39.0◦C ≤ 39.4◦C −0.15 0.13 0.86 (0.67–1.11) 0.25
39.5◦C ≤ 39.9◦C −0.66 0.22 0.52 (0.34–0.80) <0.01
40.0◦C ≤ −0.57 0.42 0.57 (0.25–1.28) 0.17
Vaccination status Unvaccinated - - 1.0 -
Vaccinated 0.15 0.10 1.16 (0.96–1.40) 0.13
Age (years) Age—linear 0.03 0.08 1.03 (0.89–1.20) 0.70
Age—quadratic 0.26 0.08 1.29 (1.11–1.51) <0.01
Age—cubic −0.14 0.05 0.87 (0.80–0.95) <0.01
Bold values are indicate significant findings.
aStandard Deviation.
bStandard Error.
cOdds Ratio.
d95% Confidence Interval.
Univariable analyses are available in Supplementary Table 9.
Dogs presenting with a mixed (OR 0.57, 95% CI 0.33–0.98) or
unknown (OR 0.46, 95% CI 0.25–0.85) diarrhoeic pattern were
less frequently resolved (Table 7). Though no pharmaceutical
agent prescribed exclusively were associated with significant
variant odds of resolution, when owners were provided with
dietary modification advice combined with gastrointestinal
nutraceuticals but no other therapy, such cases had increased
odds of resolution by 10 days post initial presentation (OR 2.8,
95% CI 1.3–6.1). This latter finding was also observed when
only mild, normothermic (<39.5◦C), non-haemorrhagic cases
were modelled (data not presented). There was little variation
in probability of resolution and age (Figure 2B). A cubic
polynomial term was included to model age at consultation;
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TABLE 7 | Parameter estimates from a finalised mixed effects logistic regression model, modelling on a case-level loss to follow-up and 10 day diarrhoea resolution
against a range of risk factors.
Random effect Variance SDa Variable Category β SEb ORc (95% CI)d P
LOSS TO FOLLOW-UP
Practice 0.42 0.65 Intercept 0.29 0.16 1.34 (0.98–1.82)
Site 0.24 0.49 Diarrhoea Without blood - - 1.0 -
With blood 0.15 0.10 1.16 (0.96–1.40) 0.13
Insurance status Uninsured - - 1.0 -
Insured −0.36 0.13 0.70 (0.54–0.89) <0.01
Neutered status Unneutered - - 1.0 -
Neutered −0.88 0.10 0.41 (0.34–0.51) <0.01
Vaccination status Unvaccinated - - 1.0 -
Vaccinated −1.16 0.10 0.32 (0.26–0.39) <0.01
Gastrointestinal
agent
Not prescribed - - 1.0 -
Prescribed 0.32 0.10 1.38 (1.14–1.66) <0.01
Age (years) Age—linear −0.09 0.09 0.92 (0.77–1.10) 0.35
Age—quadratic −0.38 0.09 0.69 (0.58–0.82) <0.01
Age—cubic 0.20 0.05 1.22 (1.11–1.35) <0.01
DIARRHOEA RESOLUTION
Practice 0.04 0.19 Intercept 3.50 0.29 33.00 (18.50–58.80)
Site 0.07 0.26 Vomit No vomit - - 1.0 -
Without blood 0.45 0.23 1.58 (1.01–2.46) 0.05
With blood −0.87 0.47 0.42 (0.17–1.05) 0.06
Diarrhoeic pattern Large intestinal - - 1.0 -
Mixed −0.57 0.28 0.57 (0.33–0.98) 0.04
Small intestinal −0.25 0.24 0.78 (0.48–1.25) 0.30
Unknown −0.78 0.32 0.46 (0.25–0.85) 0.01
Diet advice + GI
nutraceutical alone
Not dispensed - - 1.0 -
Dispensed 1.03 0.40 2.79 (1.27–6.12) 0.01
Age (years) Age—linear −0.33 0.19 0.72 (0.50–1.04) 0.08
Age—quadratic −0.44 0.19 0.65 (0.44–0.94) 0.02
Age—cubic 0.20 0.11 1.22 (0.98–1.52) 0.08
Bold values are indicate significant findings.
aStandard Deviation.
bStandard Error.
cOdds Ratio.
d95% Confidence Interval.
no interaction terms significantly improved the fit of
the model.
DISCUSSION
Canine acute diarrhoea is a frequent cause of presentation
to primary veterinary practice (5); a range of aetiologies are
associated with diarrhoea (6), a minority of which can be life
threatening (9). When cases are first presented, practitioners
need to make complex decisions around case management,
often in the absence of any specific diagnosis (5). There is a
need to understand these choices and to explore new ways of
evidencing their effect, particularly in the context of systemic
antimicrobial prescription. Here we used EHRs collected from a
large number of veterinary practices, supplemented by structured
questionnaire responses, to describe clinical signs exhibited by
dogs with acute diarrhoea, characterise common management
and treatment strategies, and assess the outcome of cases
observed longitudinally.
This study represented the first attempt to harness overall
veterinary-assessed opinion of case severity, with the vast
majority being described as mild (83.6%). Only 17 cases were
classed as severe, with six of these being euthanised on initial
presentation. Whilst this limited our ability to describe severe
disease, our findings further confirmed diarrhoea as primarily a
mild condition in dogs (1). In this study, the majority of cases
presented with non-vomiting, non-haemorrhagic diarrhoea,
broadly consistent with previous studies (2, 5). However,
diarrhoea with blood (41% of cases) and vomiting (36% of
cases) was more common than previously described (25 and
18%, respectively) (5). This previous study considered all cases
of diarrhoea regardless of clinical sign duration, also observing
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“uncomplicated diarrhea” (absence of vomiting or haemorrhagic
diarrhoea) to be more common in cases of longer disease
duration. This suggests that the presence of clinical signs
potentially alarming to owners’ e.g., haemorrhagic diarrhoea,
might prompt these owners to seek veterinary attention more
rapidly, potentially explaining the higher prevalence of such signs
recorded here in acute cases.
Diagnostic tests were rarely used in this population (9% of all
cases), and less commonly than previously reported (3, 5). This
might again reflect the primary presentation nature of this study,
and the generally mild nature of the reported disease. Hence, it
can be reasonably assumed that most prescriptions described in
this population were empirical, particularly considering that the
majority were provided at initial presentation rather than over
the following 10 days. Medical prescribers often perceive pressure
to implement a material management plan (30) which may lead
to unnecessary prescriptions, including those for antimicrobials
(31); it is possible that such pressures might also influence
veterinary prescription decisions (32). Diagnostic investigation
should take place if an infectious aetiology is suspected (33).
Unfortunately, it was not possible to determine the number
of cases where the consulting veterinary professional suspected
such an infectious aetiology in this study; such analyses could
be of considerable future value, particularly in relation to
antimicrobial stewardship.
Presence of blood in diarrhoea was significantly associated
with increased odds of a systemic antimicrobial prescription
being provided. This has been previously observed (5), and
likely reflects a perception of increased bacteraemia risk (33).
However, there is increasing evidence to suggest antimicrobial
therapy is not required in such cases (9, 10, 15, 23), with a recent
study finding a significant proportion of canine AHDS patients
fulfilling clinical bacteraemia criteria actually tested negative on
blood culture (9). Odds of a systemic antimicrobial prescription
were also increased for all body temperature categories exceeding
39.0◦C. Of note, body temperature was inconsistently recorded,
revealing a limitation of clinical narrative analyses. Nevertheless,
our findings suggest differences of opinion as to what body
temperature would indicate presence or high risk of bacteraemia.
Although pyrexia has been defined as body temperature in
excess of 39.7◦C (34), previous studies focusing on diarrhoea
have variably defined pyrexia/hyperthermia between 38.8 and
39.5◦C (2, 22), even altering definition by dog size (9). This
study identified that 35.7% of normothermic (under 39.5◦C),
mild, non-haemorrhagic cases (n = 1,050) still prescribed
systemic antimicrobials at initial presentation. On this evidence,
it would thus seem that our study has identified a reasonable
proportion of cases not at clear risk of sepsis treated with systemic
antimicrobials regardless, in contravention to current prescribing
guidance5. Hence, establishing a consistent definition of sepsis
risk may be of some importance for effective antimicrobial
stewardship. Assisting practitioner identification of patients at
risk of sepsis remains a challenge across veterinary and medical
care (35). In the absence of a specific diagnosis, clinical scoring
5PROTECT ME. Available from: https://www.bsava.com/Resources/Veterinary-
resources/PROTECT-ME
has previously been successfully utilised to uniformly measure
clinical severity and response to therapy (9, 10, 22). It could
be of value to define more universal indicators of sepsis, and
to investigate the potential benefit which could be gained, both
epidemiologically and practically, from routinely applying such
methods in first opinion practice.
The most frequently prescribed systemic antimicrobial in this
study wasmetronidazole, consistent with previous studies (5, 21).
This finding also suggests that the predominant concern of the
prescribing veterinary surgeon is treatment of anaerobic bacterial
species e.g., Clostridium perfringens, though the causative role
of such bacteria in gastrointestinal disease has recently been
brought into question (16). Further, current prescribing guidance
recommends metronidazole use for chronic diarrhoea/chronic
enteropathy treatment trials alone once all other diagnostic
test and empirical treatment options have been exhausted (36),
again suggesting limited compliance with existing guidance. In
total, systemic antimicrobials were prescribed to 50% of cases,
comparable or lower than previously described (46.5, 63, and
71%) (2, 5, 7). We have recently identified an approximately 30%
reduction in systemic antimicrobial prescription in consultations
for gastrointestinal disease between 2014 and 2018 (and a
simultaneous approximately 25% increase in gastrointestinal
nutraceutical prescription frequency) (37). Though it was not
possible to observe a direct change in management approach
by individual veterinary surgeons as repeated measures per
surgeon were not recorded, our findings here could suggest
that the manner with which veterinary surgeons manage
gastroenteric disease and acute canine diarrhoea is changing.
However, a prospective cohort study might be better placed to
demonstrate this more definitively. If present, this finding might
reflect increased awareness of voluntary prescribing guidance
recommending antimicrobial therapy to be reserved only for
acute diarrhoea cases exhibiting, or at risk, of bacteraemia
or sepsis. We further recognise the opportunities afforded by
providing prescription benchmarking statistics to practitioners,
enabling them to effectively reflect on their own decision-making
and consider changing as a result. Indeed this is an area of
active development for us currently through projects such as
“mySavsnetAMR;” all practices participating in SAVSNet also
enjoy free access to a secure, anonymised benchmarking website
for this purpose (38).
In contrast to systemic antimicrobial prescription,
gastrointestinal nutraceutical dispensing frequency was
considerably greater than in a previous study (61% of cases
compared to 26%) (2). Study methodological differences
accepted, it has been suggested that gastroenteric nutraceuticals
may form a “no harm” alternative to antibiosis in order to
effectively manage owner treatment plan expectations (32).
Of further interest, our findings suggest that a combination of
dietary modification and gastrointestinal nutraceuticals without
prescription of any studied pharmaceutical agent could aid
resolution of diarrhoeic clinical signs. Though evidence remains
scarce, previous studies have suggested that probiotics might
be efficacious in ameliorating infectious, non-infectious or
idiopathic diarrhoea in dogs (25); it is possible that we might
be observing such an effect here. However, since we have
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not randomised cases into treatment groups, there remains a
possibility of bias according to over-simplification of clinical
severity scoring as used here (39). Therefore, whilst evidence of
in vivo efficacy of gastrointestinal nutraceuticals remains limited
(25) we advocate some continued caution over wholeheartedly
embracing nutraceutical use. As with all other areas of veterinary
practice, clear clinical evidence when available should drive
decision making, and when unavailable efforts should be made
to fill such gaps in knowledge. As such, we believe the field is
now ready for a fully randomised pragmatic trial to provide
more definitive evidence surrounding the clinical benefit (or
absence thereof) of prescribing antimicrobials and other agents
to manage acute canine diarrhoea.
Regarding endoparasiticides/endectocides, weight loss was
significantly associated with increased odds of prescription,
possibly reflecting the view that weight loss is often associated
with parasitic infection (33). It should be remembered that
some endoparasiticides/endectocides6 (as well as gastrointestinal
nutraceuticals) are available without the need of a prescription
such that it is likely we have under-estimated the actual use
of these agents in this study. Similarly, this study focused on
in-consultation prescription decisions; expanding its scope to
include EHRs for referred animals and in-patient (hospitalised)
records would more completely represent all aspects of
companion animal practice.
The effect of the animal’s age on odds of pharmaceutical
prescription were complex and could be separated into
two groups: systemic antimicrobials or gastrointestinal agents
were prescribed more commonly to older animals, whereas
endoparasiticides/endectocides or gastrointestinal nutraceuticals
were prescribed more commonly to younger animals, possibly
reflecting increased parasitic or viral infection in puppies (33,
40). On univariable analyses, odds of a case being considered
moderate or severe did increase with age (data not presented);
however, including severity as an interaction with age did not
improve the fit of the model.
Classical approaches to defining the benefit of particular
treatments is to use randomised control trials, systematic reviews
or meta-analyses. For canine gastroenteritis treated in primary
care, trials of any form whether randomised or not are limited
in number, and generally small in size (9, 10, 22), such that
there is a dearth of evidence with which practitioners can base
their treatment choices. One route to increasing evidence and
complementing the highest level data from trials are pragmatic
and observational studies using EHRs collected at scale (41).
Here, our observational approach suggests no clear link between
any therapy choice and outcome; a finding corroborated for
antimicrobial therapy by earlier smaller studies (9, 10, 22).
There is an increasing pressure on both medical and veterinary
prescribers to make responsible therapeutic decisions, reflecting
best available clinical evidence (19), and our findings would
appear to broadly support the view that using antimicrobials for
management of acute diarrhoea is largely unnecessary (10).
6Veterinary Medicines Directorate product information database. Available from:
www.vmd.defra.gov.uk/ProductInformationDatabase/Default.aspx
Whilst the purely observational approach used here was
useful, this study was limited by nearly a quarter of cases
being lost to follow-up. Without specific intervention, it is
impossible to determine whether these cases simply recovered,
moved to another veterinary practice, opted out of further
SAVSNET participation, or died. However, we did show insured,
neutered, or vaccinated dogs to be associated with significantly
decreased odds of being lost to follow-up, suggesting either
owners of such dogs are more likely to engage with regular
veterinary care, or their vets are more likely to request follow
up consultations. Similarly, the odds of being lost to follow-
up also broadly increased as an animal’s age increased. Whilst
this might represent increased odds of death (42), it might
also suggest that as owners become more experienced with
their pet, they are less likely to re-present with their dog when
investigating/treating disease.
Defining outcome in an observational study of this type
presents certain challenges. When reviewing cases that re-
presented within 10 days of initial presentation, dogs often
re-presented at the request of the veterinary surgeon, or re-
presented for an unrelated complaint (data not presented). We
therefore concluded that time between initial and subsequent
presentations alone to be an unreliable measure of clinical
resolution and response to treatment. Thus, we used a 10
day period as a broad representation of the acute diarrhoea
therapy period (9, 10, 22, 33), subsequently using MPC between
11 and 30 days as an indicator of gastroenteric clinical sign
persistence or re-emergence. Though seemingly appropriate, loss
to follow-up limited our ability to fully characterise clinical
resolution. In addition, considerable therapeutic management
diversity was seen; this represents a significant challenge
when seeking to define the effect of each pharmaceutical
intervention which would only be compounded if we had also
considered additional factors such as dosage or course length.
Here we focused on five pharmaceutical classes commonly
prescribed to diarrhoea cases (2); other pharmaceutical classes
were prescribed which might also have had an impact
on clinical resolution. Considering these limiting factors, a
more structured approach, including contacting owners after
initial presentation, could complement the more observational
approach taken here.
The issues posed by veterinary surgeons failing to record, or
variably recording information within the clinical narrative has
been previously noted (7). We also observed such difficulties
(e.g., body temperature recording), though we found combining
compulsory randomised questionnaire data with the EHR to at
least partiallymitigate this issue (e.g., case severity). To encourage
engagement, the questionnaire was only deployed in a small
proportion of randomly selected relevant consultations; the cases
studied here therefore only represent a small percentage of
cases available within the SAVSNET database. It should also
be remembered that questionnaire responses were self-defined;
individual variation in case definition is therefore possible. As
text mining capabilities advance (7), the confidence with which
we could identify and follow cases using such approaches is
likely to increase, potentially unlocking a considerably greater
number of cases for analyses. However, in the mean time we
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would advocate the use of a combined textual and questionnaire
response analysis as demonstrated here.
CONCLUSIONS
This study successfully demonstrated the ability of combined
structured, semi-structured and unstructured data to characterise
factors associated with pharmaceutical prescription in acute
canine diarrhoea cases. Not surprisingly, we saw considerable
therapeutic diversity between cases, a number of which
contradicted current prescribing guidance. Considering
the threat posed by antimicrobial resistance especially, this
suggests that latest clinical evidence is not effectively being
disseminated throughout the profession. The findings presented
here complement other studies, and suggests that efforts
should be re-doubled to effectively disseminate latest clinical
evidence to the wider, and particularly first opinion, veterinary
profession. Though future methodological improvements are
recommended, this study broadly supports the view that systemic
antimicrobials are largely unnecessary in acute diarrhoea cases.
The only intervention positively associated with resolution odds
was provision of dietary modification advice and gastrointestinal
nutraceuticals; hence we would urgently recommend further
work exploring the precise impact of prebiotics, probiotics etc.
on gastrointestinal health in our canine population.
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